AFFIMED N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.3 USD | -0.56% |
|
+8.61% | -15.20% |
| 01/04 | Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating | MT |
| 01/04 | HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating | MT |
Chart calendar Affimed N.V.
3.oB1V0eAiKhfqAdM8cJFlfxPcFGl9yvdsy58XCneRrXg.kWQTq7JjbE2BaJ5NNtgHDVeVd10Ei7xfuvZuXh743hXCZCyf1kZpXplYgg~d09e1bf991c7af1ec76ad5ff91326c25
Upcoming events on Affimed N.V.
Past events on Affimed N.V.
| 28/03/2024 06:00 pm | Q4 2023 Earnings Call |
| 28/03/2024 04:00 pm | Q4 2023 Earnings Release |
| 12/12/2023 07:30 am | American Society of Hematology Meeting - AFM13 in Combination with Allogeneic Natural Killer Cells |
| 12/12/2023 03:00 am | American Society of Hematology Meeting |
| 12/12/2023 01:15 am | American Society of Hematology Meeting - Innate Cell Engager |
| 15/11/2023 07:00 pm | Jefferies London Healthcare Conference |
| 14/11/2023 07:00 pm | Q3 2023 Earnings Call |
| 14/11/2023 05:00 pm | Q3 2023 Earnings Release |
| 14/11/2023 | PEGS Europe Conference |
| 08/11/2023 | Truist Securities Healthcare Conference |
| 04/11/2023 05:40 am | Society for Immunotherapy of Cancer Meeting - Abstract Number: 329 |
| 04/11/2023 12:30 am | Society for Immunotherapy of Cancer Meeting - Abstract Number: 329 |
| 28/09/2023 10:45 pm | Cantor Global Healthcare Conference |
| 26/09/2023 | NK Society for Natural Immunity Meeting |
| 12/09/2023 08:30 pm | H.C. Wainwright Global Investment Conference |
| 10/08/2023 06:00 pm | Q2 2023 Earnings Call |
| 10/08/2023 04:00 pm | Q2 2023 Earnings Release |
| 03/08/2023 08:15 am | American Society of Clinical Oncology Conference - Poster Number: 26 |
| 21/06/2023 05:30 pm | Annual General Meeting |
| 15/06/2023 08:30 pm | Malignant Lymphoma International Conference - Abstract No 126 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 21,4 19,8 7.93% | 28,4 32,0 -11.48% | 40,4 38,3 5.47% | 41,4 37,6 9.95% | 8,28 9,48 -12.74% | 5,39 |
|
EBITDA Million EUR | Released Forecast Spread | 0,00 0,00 - | -33,6 -32,0 -5.01% | -62,7 -60,7 -3.37% | -85,2 -80,0 -6.53% | 0,00 0,00 - | 0,00 |
|
EBIT Million EUR | Released Forecast Spread | -32,4 -35,1 7.83% | -34,7 -24,9 -39.48% | -64,0 -61,4 -4.22% | -88,1 -87,7 -0.53% | -107 -111 3.93% | -89,1 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -32,4 -33,5 3.45% | -41,4 -28,0 -47.78% | -57,5 -55,9 -2.92% | -86,0 -83,6 -2.85% | -106 -109 3.02% | -89,2 |
|
Net income Million EUR | Released Forecast Spread | -32,4 -33,1 2.35% | -41,4 -27,1 -52.48% | -57,5 -55,6 -3.54% | -86,0 -82,8 -3.9% | -106 -109 2.69% | -88,0 |
|
EPS EUR | Released Forecast Spread | -5,00 -5,06 1.19% | -5,00 -3,27 -53.14% | -4,80 -4,69 -2.35% | -6,00 -5,78 -3.87% | -7,09 -7,28 2.65% | -4,81 |
| Announcement Date | 28/04/20 | 15/04/21 | 31/03/22 | 23/03/23 | 28/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 10,3 7,88 31.14% | 8,01 9,29 -13.79% | 7,30 7,63 -4.27% | 14,9 7,40 101.23% | 11,2 6,52 71.14% | 4,51 5,70 -20.89% | 1,39 4,32 -67.81% | 1,96 1,89 3.98% | 0,41 1,55 -73.39% | 1,26 | 1,12 | 1,10 | 1,14 | 0,00 |
|
EBITDA Million EUR | Released Forecast Spread | -23,8 -22,5 -5.68% | -21,3 -22,8 6.53% | ||||||||||||
|
EBIT Million EUR | Released Forecast Spread | -24,2 -21,8 -10.77% | -17,1 -25,3 32.29% | -21,7 -23,3 6.92% | -19,2 -27,1 29.2% | -30,1 -30,3 0.69% | -31,5 -28,8 -9.33% | -29,4 -28,4 -3.74% | -24,9 -28,2 11.75% | -20,8 -24,8 16.06% | -24,7 | -24,3 | -21,8 | -21,7 | |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -23,1 -20,8 -11.01% | -16,7 -23,0 27.53% | -19,4 -24,0 19.28% | -16,5 -28,0 41.14% | -33,4 -30,7 -8.83% | -32,0 -28,2 -13.39% | -29,4 -26,6 -10.63% | -24,4 -27,4 11.25% | -20,2 -24,1 16.21% | -23,2 | -23,1 | -24,2 | -23,5 | |
|
Net income Million EUR | Released Forecast Spread | -23,1 -19,0 -21.43% | -16,7 -21,5 22.32% | -19,4 -23,9 18.63% | -16,5 -26,9 38.66% | -33,4 -29,8 -12.09% | -32,0 -28,7 -11.56% | -29,4 -27,9 -5.42% | -24,4 -27,5 11.54% | -20,2 -23,6 14.44% | -24,1 | -23,9 | -21,7 | -21,1 | |
|
EPS EUR | Released Forecast Spread | -1,90 -1,61 -18.22% | -1,40 -1,81 22.6% | -1,30 -1,70 23.42% | -1,10 -1,79 38.5% | -2,20 -1,94 -13.26% | -2,10 -1,92 -9.46% | -2,00 -1,90 -5.4% | -1,60 -1,84 13.1% | -6,52 -1,57 -316.61% | -1,55 | -1,28 | -1,10 | -1,07 | -0,82 |
| Announcement Date | 31/03/22 | 01/06/22 | 11/08/22 | 15/11/22 | 23/03/23 | 23/05/23 | 10/08/23 | 14/11/23 | 28/03/24 | - | - | - | - | - |
More events
Past sector events for Affimed N.V.
| 03/05/2024 01:35 am | KURA ONCOLOGY, INC.: Q1 2024 Earnings Release |
| 03/05/2024 01:35 am | ZYMEWORKS INC.: Q1 2024 Earnings Release |
| 03/05/2024 01:32 am | ARDELYX, INC.: Q1 2024 Earnings Release |
| 03/05/2024 01:31 am | LONGBOARD PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 03/05/2024 01:31 am | ASCENDIS PHARMA A/S: Q1 2024 Earnings Release |
| 03/05/2024 01:30 am | ULTRAGENYX PHARMACEUTICAL INC.: Q1 2024 Earnings Release |
| 02/05/2024 08:30 pm | GENMAB A/S: Q1 2024 Earnings Release |
| 02/05/2024 04:30 pm | GERON CORPORATION: Q1 2024 Earnings Release |
| 02/05/2024 04:30 pm | AGIOS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 04:30 pm | BICYCLE THERAPEUTICS PLC: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- AFMD Stock
- Calendar Affimed N.V.
